Abstract：Objective To explore the relationship between the levels of serum lipoprotein phospholipase A2 (Lp-PLA2), non-esterified fatty acid (NEFA) and severity of coronary artery disease. Methods A total of 100 patients with coronary heart disease diagnosed and treated in Yankuang New Journey General Hospital (“our hospital” for short) from July 2016 to December 2018 were selected as the observation group, and a total of 50 healthy patients who underwent physical examination in our hospital during the same period were selected as the control group. The levels of serum LP-PLA2 and NEFA were recorded anong the two groups, patients with different disease counts and patients with different Gensini scores, and the correlation was analyzed. Results The levels of serum LP-PLA2 and NEFA in the observation group were significantly higher than those in the control group, and the differences were statistically significant (P ＜ 0.05). The levels of serum LP-PLA2 and NEFA in patients with three-vessel disease were significantly higher than those with double-vessel and single-vessel disease, while patients with double-vessel disease were significantly higher than patients with single-vessel disease, and the differences were statistically significant (P ＜ 0.05). The levels of serum LP-PLA2 and NEFA of patients with Gensini score＞39 points were significantly higher than those other scores, while patients with Gensini scores of 20 to 39 were significantly higher than those with Gensini scores of＜20 points, and the differences were statistically significant (P ＜ 0.05). The levels of serum LP-PLA2, NEFA were positively correlated with the number of lesions (r = 0.592, 0.450, P ＜ 0.05) and Gensini score (r = 0.598, 0.468, P ＜ 0.05). Conclusion The levels of serum LP-PLA2 and NEFA in patients with coronary heart disease are elevated, while the levels of serum LP-PLA2 and NEFA are closely related to the severity of coronary artery disease, and have certain clinical value in the diagnosis and treatment of coronary artery disease.
朱国栋 徐林 李铮. 血清LP-PLA2、NEFA水平与冠状动脉病变严重程度的关系[J]. 中国医药导报, 2020, 17(20): 66-69.
ZHU Guodong XU Lin LI Zheng. Relationship between the levels of serum LP-PLA2, NEFA and severity of coronary artery disease. 中国医药导报, 2020, 17(20): 66-69.
[1] 郑秀琴，黄江英.高血压前期的流行病学特征及其与心血管疾病危险因素及多代谢异常的相关性分析[J].包头医学院学报，2017，33（8）：92-94.
[2] 冯高科，汪小丁，陈晶晶，等.冠心病危险因素与冠脉病变程度的相关分析[J].中国医师杂志，2018，20（1）：72-75.
[3] Valtorta NK，Kanaan M，Gilbody S，et al. Original article：Loneliness and social isolation as risk factors for coronary heart disease and stroke：systematic review and meta-analysis of longitudinal observational studies [J]. Heart，2016，102（13）：1009-1016.
[4] Wang Y，Li SS，Na SP，et al. Characterization of Lipoprotein-associated Phospholipase A2 in Serum in Patients With Stage 3-5 Chronic Kidney Disease [J]. Am J Med Sci，2016，352（4）：348-353
[5] 王亚飞，李惠勉.动脉粥样硬化血栓形成性脑梗死患者血清Lp-PLA2水平变化及其意义[J].山东医药，2018， 58（11）：72-74.
[6] Zhao L，Guo X，Wang O，et al. Fructose and glucose combined with free fatty acids induce metabolic disorders in HepG2 cell：A new model to study the impacts of high-fructose/sucrose and high-fat diets in vitro [J]. Mol Nutr Food Res，2016，60（4）：909-921.
[7] Zhu CP，Li TP，Wang X，et al. The relationship between apnoea hypopnoea index and Gensini score in patients with acute myocardial infarction undergoing emergency primary percutaneous coronary intervention [J]. J Thorac Dis，2016，9（8）：2476-2483.
[8] 苏翔，赵明芬.冠心病伴焦虑抑郁状态的中医诊疗现状[J].国际中医中药杂志，2019，41（3）：321-323.
[9] Yang L，Liu Y，Wang S，et al. Association between Lp-PLA2 and coronary heart disease in Chinese patients [J]. J Int Med Res，2017，45（1）：159-169.
[10] Jackisch L，Kumsaiyai W，Moore JD，et al. Differential expression of Lp-PLA2 in obesity and type 2 diabetes and the influence of lipids [J]. Diabetologia，2018，61（5）：1155-1166.
[11] 左岩霞，李美，赵令时，等.颈动脉粥样硬化斑块与血浆脂蛋白相关磷脂酶A2的关系[J].山东医药，2008，48（42）：67-68.
[12] Gao W，Du X，Lei L，et al. NEFA-induced ROS impaired insulin signalling through the JNK and p38MAPK pathways in non-alcoholic steatohepatitis [J]. J Cell Mol Med，2018，22（7）：3408-3422.
[13] 戴雯，黄允，李艳.血清脂蛋白相关磷脂酶A2和游离脂肪酸水平与冠心病患者冠状动脉病变的关系[J].微循环学杂志，2017，27（1）：39-42.
[14] Zheng HD，Cui DJ，Quan XJ，et al. Lp-PLA2 silencing protects against ox-LDL-induced oxidative stress and cell apoptosis via Akt/mTOR signaling pathway in human THP1 macrophages [J]. Biochem Biophys Res Commun，2016，477（4）：1017-1023.
[15] Zinkevich NS，Fancher IS，Gutterman DD，et al. Roles of NADPH oxidase and mitochondria in flow-induced vasodilation of human adipose arterioles：ROS-induced ROS release in coronary artery disease [J]. Microcirculation，2017，24（6）：1-17.
[16] Kikuchi K，Setoyama K，Tanaka E，et al. Uric acid enhances alteplase-mediated thrombolysis as an antioxidant [J]. Sci Rep，2018，8（1）：15844.
[17] Yιlmaz M，Altιn C，Özyιldιz A，et al. Are oxidative stress markers helpful for diagnosing the disease and determining its complexity or extent in patients with stable coronary artery disease? [J]. Turk Kardiyol Dern Ars，2017， 45（7）：599-605.
[18] Madisetty MK，Kumaraswami K，Katkam S，et al. Assessment of Oxidative Stress Markers and Carotid Artery Intima-Media Thickness in Elderly Patients Without and with Coronary Artery Disease [J]. Indian J Clin Biochem，2016，31（3）：278-285.
[19] Reis AH. Acidemia and blood free fatty acids：Analysis of cardiovascular risk factors in a new context [J]. Discov Med，2017，23（126）：183-188.
[20] Matoba A，Matsuyama N，Shibata S，et al. The free fatty acid receptor 1 promotes airway smooth muscle cell proliferation through MEK/ERK and PI3K/Akt signaling pathways [J]. Am J Physiol Lung Cell Mol Physiol，2018， 314（3）：333-348.
[21] Jorat MV，Tabrizi R，Mirhosseini N，et al. The effects of coenzyme Q10 supplementation on lipid profiles among patients with coronary artery disease：a systematic review and meta-analysis of randomized controlled trials [J]. Lipids Health Dis，2018，17（1）：230.
[22] Eelen G，de Zeeuw P，Treps L，et al. Endothelial Cell Metabolism [J]. Physiol Rev，2018，98（1）：3-58.
[23] Fan Y，Li Y，Chen Y，et al. Comprehensive Metabolomic Characterization of Coronary Artery Diseases [J]. J Am Coll Cardiol，2016，68（12）：1281-1293.
2020, Vol. 17 
京公网安备 11010502046598号